stockportfolio.pro
Stocks / NTLA vs NUVB
NTLA vs NUVB
Intellia Therapeutics, Inc. and Nuvation Bio Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Intellia Therapeutics, Inc. (NTLA) | Nuvation Bio Inc. (NUVB) | |
|---|---|---|
| Market cap | $1.7B | $1.6B |
| Revenue (latest FY) | $67.67M | $62.90M |
| Net income (latest FY) | $-412.69M | $-204.63M |
| Revenue growth (5y CAGR) | 3.1% | — |
| Net margin | -609.9% | -325.3% |
| Return on equity | -61.5% | -66.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NTLA — free Open NUVB — freeFrequently asked questions
Which is bigger, NTLA or NUVB?
Intellia Therapeutics, Inc. is larger by market capitalization — $1.7B versus $1.6B.
Which grows faster, NTLA or NUVB?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.